CN105669964B - 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 - Google Patents
卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 Download PDFInfo
- Publication number
- CN105669964B CN105669964B CN201610123977.1A CN201610123977A CN105669964B CN 105669964 B CN105669964 B CN 105669964B CN 201610123977 A CN201610123977 A CN 201610123977A CN 105669964 B CN105669964 B CN 105669964B
- Authority
- CN
- China
- Prior art keywords
- polymer
- crosslinking
- oophoroma
- vesica
- self
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 167
- 238000004132 cross linking Methods 0.000 claims abstract description 133
- 239000003814 drug Substances 0.000 claims abstract description 130
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 62
- 229940079593 drug Drugs 0.000 claims abstract description 49
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 31
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 30
- 201000011510 cancer Diseases 0.000 claims abstract description 18
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 52
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 52
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 30
- 239000000178 monomer Substances 0.000 claims description 29
- 239000002245 particle Substances 0.000 claims description 29
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 25
- QIVCSDQYBHRWNQ-UHFFFAOYSA-N S.OC(O)=O Chemical compound S.OC(O)=O QIVCSDQYBHRWNQ-UHFFFAOYSA-N 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 19
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 14
- 229960000304 folic acid Drugs 0.000 claims description 14
- 235000019152 folic acid Nutrition 0.000 claims description 14
- 239000011724 folic acid Substances 0.000 claims description 14
- 150000003384 small molecules Chemical group 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 229930012538 Paclitaxel Natural products 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 239000005864 Sulphur Substances 0.000 claims description 7
- 229960001592 paclitaxel Drugs 0.000 claims description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 229940022353 herceptin Drugs 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 229940009456 adriamycin Drugs 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 4
- 229960000572 olaparib Drugs 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 102000002070 Transferrins Human genes 0.000 claims description 3
- 108010015865 Transferrins Proteins 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 210000004681 ovum Anatomy 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 239000003431 cross linking reagent Substances 0.000 abstract description 11
- 230000012010 growth Effects 0.000 abstract description 10
- 231100000331 toxic Toxicity 0.000 abstract description 8
- 230000002588 toxic effect Effects 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000002626 targeted therapy Methods 0.000 abstract description 3
- 238000010382 chemical cross-linking Methods 0.000 abstract description 2
- 239000000599 controlled substance Substances 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 53
- 210000004027 cell Anatomy 0.000 description 48
- 241000699666 Mus <mouse, genus> Species 0.000 description 41
- 230000008685 targeting Effects 0.000 description 38
- 210000003967 CLP Anatomy 0.000 description 34
- 101150038575 clpS gene Proteins 0.000 description 33
- 238000009826 distribution Methods 0.000 description 31
- 239000000243 solution Substances 0.000 description 26
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- 240000002853 Nelumbo nucifera Species 0.000 description 15
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 15
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 15
- 230000005311 nuclear magnetism Effects 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 238000000502 dialysis Methods 0.000 description 12
- 210000003462 vein Anatomy 0.000 description 12
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 102000004338 Transferrin Human genes 0.000 description 9
- 108090000901 Transferrin Proteins 0.000 description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 210000001672 ovary Anatomy 0.000 description 9
- 238000007789 sealing Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 239000011701 zinc Substances 0.000 description 9
- 229910052725 zinc Inorganic materials 0.000 description 9
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229920001400 block copolymer Polymers 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229960004679 doxorubicin Drugs 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 239000012581 transferrin Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 230000007547 defect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000011275 oncology therapy Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000011729 BALB/c nude mouse Methods 0.000 description 6
- -1 Polytrimethylene Polymers 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 229920002988 biodegradable polymer Polymers 0.000 description 6
- 239000004621 biodegradable polymer Substances 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 5
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000011938 amidation process Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 229940115080 doxil Drugs 0.000 description 4
- 230000002121 endocytic effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000005909 tumor killing Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000005676 cyclic carbonates Chemical class 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000000505 pernicious effect Effects 0.000 description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 235000011083 sodium citrates Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000048 toxicity data Toxicity 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 239000004425 Makrolon Substances 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000006845 Michael addition reaction Methods 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 238000000205 computational method Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 238000012805 post-processing Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 230000036326 tumor accumulation Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- MWWSFMDVAYGXBV-FGBJBKNOSA-N (7s,9s)-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC(N)C(O)C(C)O1 MWWSFMDVAYGXBV-FGBJBKNOSA-N 0.000 description 1
- CHUGKEQJSLOLHL-UHFFFAOYSA-N 2,2-Bis(bromomethyl)propane-1,3-diol Chemical compound OCC(CO)(CBr)CBr CHUGKEQJSLOLHL-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GJEAMHAFPYZYDE-UHFFFAOYSA-N [C].[S] Chemical compound [C].[S] GJEAMHAFPYZYDE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- MAHNFPMIPQKPPI-UHFFFAOYSA-N disulfur Chemical compound S=S MAHNFPMIPQKPPI-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000004186 follicle cell Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000569 greater omentum Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 108010001535 sulfhydryl oxidase Proteins 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
- C08G64/18—Block or graft polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/64—Polyesters containing both carboxylic ester groups and carbonate groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
- C08G63/688—Polyesters containing atoms other than carbon, hydrogen and oxygen containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
- C08G64/02—Aliphatic polycarbonates
- C08G64/0208—Aliphatic polycarbonates saturated
- C08G64/0225—Aliphatic polycarbonates saturated containing atoms other than carbon, hydrogen or oxygen
- C08G64/025—Aliphatic polycarbonates saturated containing atoms other than carbon, hydrogen or oxygen containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
- C08G64/20—General preparatory processes
- C08G64/30—General preparatory processes using carbonates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
- C08G64/42—Chemical after-treatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
本发明公开了一种卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡以及在卵巢癌靶向治疗中的应用。利用本发明的生物可降解双亲性聚合物得到的聚合物囊泡具有生物可降解性,可用于控制药物释放体系;在无需外加交联剂的条件下,可以自行交联,形成稳定的化学交联结构,从而可在载体支持体内稳定长循环,不仅避免了交联剂的副作用,而且该交联具有还原敏感性,在细胞内快速解交联、最大量释放出药物,高效特异性地杀死癌细胞,有效抑制卵巢肿瘤的生长而不造成毒副作用;更为重要的,无外加交联剂有利于纳米药物临床应用生产,降低了生产成本,还提高了纳米药物的最终纯度,提高了其生物相容性;同时还避免了交联剂对一些药物的干扰。
Description
技术领域
本发明涉及一种生物可降解聚合物材料及其应用,具体涉及一种卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡以及在卵巢癌靶向治疗中的应用,属于医药材料领域。
背景技术
生物可降解聚合物具有非常独特的性能而被广泛应用于生物医学的各个领域,如手术缝合线、骨固定器械、生物组织工程支架材料和药物控制释放载体等。合成的生物可降解聚合物主要有脂肪族聚酯(聚乙交酯PGA、聚丙交酯PLA、丙交酯-乙交酯共聚物PLGA、聚己内酯PCL)、聚碳酸酯(聚三亚甲基环碳酸酯PTMC)等是最常用的生物可降解聚合物,已获得美国食品药物管理部门(FDA)的许可。但是,现有的生物可降解聚合物如PTMC、PCL、PLA和PLGA 等结构比较单一,缺乏可修饰官能团,往往难以提供循环稳定的药物载体。聚碳酸酯的降解产物主要是二氧化碳和中性的二元醇,不产生酸性降解产物。其中功能性环状碳酸酯单体可和环酯类单体如GA、LA和ε-CL等,以及其它环状碳酸酯单体共聚,得到不同性能的生物可降解聚合物。另外,由现有技术制备的生物可降解聚合物得到的生物可降解纳米载体存在体内循环不稳定、肿瘤细胞摄取低、细胞内药物浓度低的问题,这导致纳米药物的药效不高,还存在毒副作用。由功能性生物可降解聚合物可制备胶束纳米药物在体内循环稳定,但只能装载疏水性小分子抗癌药物,而对穿透能力更强的亲水性小分子抗癌药物无能为力,极大地限制了其作为药物载体的应用。
癌症是威胁人类健康的主要杀手,其发病率和死亡率呈逐年上升的趋势。卵巢癌是卵巢肿瘤的一种恶性肿瘤,是指生长在卵巢上的恶性肿瘤,其中90%~95%为卵巢原发性的癌,另外5%~10%为其他部位原发的癌转移到卵巢。由于卵巢的胚胎发育、组织解剖及内分泌功能较复杂,它所患的肿瘤可能为良性或恶性。由于卵巢癌早期缺少特异性症状,筛查作用又有限,鉴别其组织类型及良恶性相当困难,因此早期诊断比较困难,卵巢癌行剖腹探查术中发现肿瘤局限于卵巢的仅占30%,大多数已扩散到子宫双侧附件,大网膜及盆腔各器官;就诊时60%~70%已为晚期,而晚期病例疗效不佳。直到目前为止,卵巢癌无论在诊断和治疗上确是一大难题。因此,虽然卵巢癌的发病例低于宫颈癌和子宫内膜癌居妇科恶性肿瘤的第三位,但死亡率却超过宫颈癌和子宫内膜癌之和,高居妇科癌症首位,是严重威胁妇女健康的最大疾患。
简而言之,卵巢癌是高发性的女性恶性肿瘤,虽然发病的绝对人数不是很多,但是死亡率很高,主要是由于早期难以觉察,难以早期诊断,多数一经诊断即为晚期,错过了手术切除的最佳时间;而且其治疗还存在着治愈率低、易转移、易耐药的特点。而纳米药物能够改变传统化疗药物的体内分布,增强肿瘤内药物的浓度,提高治疗效果,是治疗卵巢癌的一个关键点和希望所在。DOXIL(PEG化的脂质体阿霉素)是FDA批准使用最早的一个脂质体囊泡纳米药物DOXIL(PEG化的脂质体阿霉素),临床上对卵巢癌的治疗有效。但是,DOXIL也存在问题。其一是其最大耐受剂量(MTD)较小,故治疗窗口相对较窄、还有易出现毒副作用的问题;其二,DOXIL是基于EPR效应的被动靶向作用,由于不同肿瘤的巨大的个体差异性,很难利用一个通用的统一机理来把纳米药物运输到所有的肿瘤组织和肿瘤细胞中(参见:S. Eetezadi, SN. Ekdawi, C. Allen, Adv. Drug Deliv Rev, 2015, 91, 7-22);对于不同肿瘤,由于不同肿瘤表面性质差别很大,相同肿瘤在不同病人间的差别也很大;即便是同一个肿瘤中不同的肿瘤细胞也不尽相同,因此个性化的治疗显得尤为重要。因此我们必须个性化地设计适合目标肿瘤的靶向体系,而不能把适用于一个适应症的药物随便用到其他病症上,因此个性化的治疗显得尤为重要。所以,需要研发针对特定肿瘤的主动靶向纳米药物,具有肿瘤特异性,来实现纳米药物的其他的优点如提高肿瘤细胞的有效药物浓度、提高体内外的疗效。
发明内容
本发明的目的是提供一种卵巢癌特异靶向的生物可降解双亲性聚合物及其制备的聚合物囊泡以及作为抗卵巢癌药物的载体在制备卵巢癌靶向治疗药物中的应用。
为达到上述目的,本发明具体的技术方案为:
一种卵巢癌特异靶向的生物可降解双亲性聚合物,由含双硫碳酸酯单体的聚合物键合靶向分子制备得到;所述靶向分子为GE11(多肽)、FA(叶酸)、转铁蛋白(transferrin)或者Herceptin蛋白;所述含双硫碳酸酯单体的聚合物的化学结构式为以下结构式中的一种:
式Ⅰ
式Ⅱ
其中, R1选自以下基团中的一种:
R2选自以下基团中的一种:
、、;
其中,k为113~170,x为15~45,y 为80~300,m 为220~280。
本发明公开的含双硫碳酸酯单体的聚合物的疏水嵌段具有侧链含双硫五元环功能基团的环碳酸酯单元;可以为二嵌段聚合物:
也可以为三嵌段聚合物:
优选的技术方案中,R1选自以下基团中的一种:
所述R2选自以下基团中的一种:
、;
所述k为113~170,x为20~40,y 为125~250。
优选的,当含双硫碳酸酯单体的聚合物的化学结构式为式Ⅰ时,分子量为30~55kDa;当含双硫碳酸酯单体的聚合物的化学结构式为式Ⅱ时,分子量为60~95 kDa;本发明公开的聚合物的分子量可控,其各结构单元的组成和比例适合于形成自交联形成稳定的聚合物囊泡结构。
本发明公开的卵巢癌特异靶向的生物可降解双亲性聚合物具有生物可降解性,其疏水部分的分子量是亲水部分分子量的三倍左右及以上,可通过溶剂置换法、透析法或薄膜水化法等方法来制备得到聚合物囊泡结构。制备的聚合物囊泡为纳米尺寸,粒径50~160纳米,可以作为治疗卵巢癌的药物的载体;在囊泡的疏水膜中装载疏水性小分子抗卵巢癌药物紫杉醇、多西紫杉醇、阿霉素、奥拉帕尼、吉非替尼等,也可以在囊泡的大亲水内腔中装载亲水性抗卵巢癌药物,尤其是亲水性小分子抗癌药物如盐酸多柔比星、盐酸表阿霉素、盐酸伊利替康和盐酸米托蒽醌。这样克服了现有的由双亲性聚合物形成的胶束载体只能装载疏水药物的缺陷和现有技术中没有能高效装载、并稳定体内循环的亲水性小分子抗癌药物的载体的缺陷。
本发明还公开了一种聚合物囊泡,可以由上述含双硫碳酸酯聚合物含双硫碳酸酯单体的聚合物制备得到;或者由上述卵巢癌特异靶向的生物可降解双亲性聚合物制备得到;或者由上述含双硫碳酸酯聚合物含双硫碳酸酯单体的聚合物与卵巢癌特异靶向的生物可降解双亲性聚合物制备得到,比如上述含双硫碳酸酯聚合物含双硫碳酸酯单体的聚合物和卵巢癌特异靶向的生物可降解双亲性聚合物按照不同比例混合,可制备具有不同靶向密度的聚合物囊泡,即得到卵巢癌靶向自交联囊泡,来可以增加囊泡纳米药物在卵巢癌细胞中的摄取量;也可以由含双硫碳酸酯聚合物含双硫碳酸酯单体的聚合物制备的囊泡的外表面偶联肿瘤细胞特异性靶向分子来制备卵巢癌靶向囊泡,以增加卵巢癌细胞的摄取量,比如在囊泡的PEG端通过迈克尔加成或酰胺化反应键合GE11、FA、transferrin或者Herceptin等。优选的,本发明的聚合物囊由卵巢癌特异靶向的生物可降解双亲性聚合物与含双硫碳酸酯聚合物含双硫碳酸酯单体的聚合物制备得到;按质量百分数,所述卵巢癌特异靶向的生物可降解双亲性聚合物的用量为1~40 wt.%。
本发明的含双硫碳酸酯单体的聚合物和卵巢癌特异靶向的生物可降解双亲性聚合物可在不加入任何物质的情况下自行交联,得到自交联聚合物囊泡。聚合物作为药物载体应用时,为达到最佳靶向和治疗效果,最基本也是最关键的性能为就是在体内长时间循环。而形成交联结构是聚合物载体能够在体内环境长时间循环的必要过程,现有技术都是通过添加交联剂使得聚合物纳米载体形成稳定的交联结构,但是交联剂的加入,不仅会增加纳米药物制备流程的复杂程度、增加纳米药物的生产成本、降低药物的最终纯度,不利于纳米药物临床应用的放大生产,还会影响药物装载效率、药物释放水平,并增加毒副作用、降低聚合物载体纳米药物的生物相容性;本发明首次公开的聚合物结构,可以在无需外加交联剂的条件下,自行交联,而在囊泡疏水膜内形成稳定的化学交联结构,从而可在体内稳定长循环,不仅避免了交联剂的副作用,而且在载药聚合物囊泡到达肿瘤并内吞进入癌细胞后,在细胞内大量还原性物质存在环境下,可以快速解交联,最大量释放药物,高效杀死卵巢癌细胞;同时自交联聚合物的稳定性等同甚至优于交联剂交联聚合物囊泡;更为重要的,本发明避免了交联剂对一些药物的干扰,成功利用自交联聚合物囊泡装载药物,不仅避免了现有小分子药物的副作用,拓展抗癌药物的利用空间,而且可以适用体质差异大的不同个体。
本发明还公开了上述卵巢癌特异靶向的生物可降解双亲性聚合物在制备治疗卵巢癌的纳米药物中的应用;进一步的地,本发明还公开了上述聚合物囊泡在制备治疗卵巢癌的纳米药物中的应用;尤其保护自交联聚合物囊泡作为载体在制备治疗卵巢癌的药物中的应用,自交联聚合物囊泡避免交联剂的使用,进一步增强了药物安全性,减少药物组装步骤。基于本发明聚合物制备的抗卵巢癌纳米药物为囊泡抗卵巢癌纳米药物。
由于上述方案的实施,本发明与现有技术相比,具有以下优点:
1. 本发明公开的侧链含双硫的生物可降解双亲性聚合物具有生物可降解性、优异的卵巢癌靶向性,可以制备聚合物囊泡,装载不同性质的药物,可以不加入任何交联剂而自行交联,形成稳定的自交联聚合物囊泡纳米药物,从而克服了现有技术中纳米药物体内循环不稳定、药物易早释、造成毒副作用的缺陷。
2. 本发明公开的自交联囊泡纳米药物的交联具有可逆性,即支持体内长循环,可在卵巢癌细胞高富集;但是进入卵巢癌细胞内后却可以快速解交联,释放出药物,实现高效特异性地杀死卵巢癌细胞而不具有毒副作用,克服了现有技术中交联纳米药物过于稳定、而在细胞内药物释放缓慢、造成耐药性的缺陷。
3. 本发明公开的卵巢癌特异靶向的生物可降解双亲性聚合物可以不加入任何交联剂而制备自交联囊泡,制备方法简便,从而克服了现有技术中制备交联纳米药物时候存在的必须加入交联剂等物质以及需要复杂的操作和提纯过程等缺陷,有利于纳米药物的临床应用。
4. 本发明公开的卵巢癌特异靶向的生物可降解双亲性聚合物自组装制备的自交联聚合物囊泡可用于亲水小分子抗癌药物的控制释放体系,从而克服了现有生物可降解纳米胶束载体仅适用装载疏水小分子药物的缺陷和现有技术中没有能高效装载、并稳定体内循环的亲水性小分子抗癌药物的缺陷;进一步地,可制备卵巢癌靶向的自交联囊泡,在卵巢癌的高效靶向治疗方面具有更广泛的应用价值。
附图说明
图1是实施例十五中交联囊泡PEG5k-P(CDC5.8k-co-TMC23k)粒径分布(A)及电子投射显微镜图片(B),交联囊泡稳定性的测试(C)及还原响应性测试(D)图;
图2为实施例二十中载DOX·HCl交联囊泡PEG5k-P(CDC5.8k-co-TMC23k)的体外释放图;
图3 是实施例二十中载DOX·HCl交联囊泡GE11-CLPs的体外释放图;
图4 是实施例二十一中靶向交联囊泡GE11-CLPs对SKOV3卵巢癌细胞的毒性结果图;
图5是实施例二十二中载DOX·HCl靶向交联囊泡GE11-CLPs对SKOV3卵巢癌细胞的毒性结果图;
图6是实施例二十二中载DOX·HCl靶向交联囊泡GE11-CLPs对SKOV3卵巢癌细胞的半致死量毒性结果图;
图7为实施例二十四中载DOX·HCl靶向交联囊泡GE11-CLPs 对SKOV3卵巢癌细胞的细胞内吞结果图;
图8 为实施例二十九中载DOX·HCl靶向交联囊泡GE11-CLPs对小鼠的血液循环结果图;
图9为实施例三十中载DOX·HCl靶向交联囊泡GE11-CLPs对荷皮下卵巢癌小鼠的生物分布结果图;
图10为实施例三十一中载DOX·HCl靶向交联囊泡GE11-CLPs对小鼠的最大耐受量结果图;
图11 为实施例三十二中载DOX·HCl靶向交联囊泡GE11-CLPs在皮下荷卵巢癌小鼠的多剂量治疗图,其中A为肿瘤生长曲线,B为小鼠治疗后肿瘤图片,C为体重变化,D为生存曲线;
图12为实施例三十三中载DOX·HCl靶向交联囊泡GE11-CLPs在皮下荷卵巢癌小鼠的单剂量治疗图,其中A为肿瘤生长曲线,B为小鼠治疗后肿瘤图片,C为体重变化曲线,D为生存曲线。
具体实施方式
下面结合实施例和附图对本发明作进一步描述:
实施例一 含双硫五元环功能基团的环状碳酸酯单体(CDC)的合成
一水合硫氢化钠(28.25 g,381.7 mmol)溶在400 mL N,N-二甲基甲酰胺(DMF)中,50℃加热至完全溶解,逐滴加入二溴新戊二醇(20 g,76.4 mmol),反应48小时。反应物减压蒸馏除去溶剂DMF,然后用200mL蒸馏水稀释,用250 mL乙酸乙酯萃取四次,最后有机相旋蒸得到黄色粘稠状化合物A,产率:70%;溶解在400 mL的四氢呋喃(THF)中的化合物A在空气中放置24小时,分子间巯基氧化成硫硫键,得到化合物B,产率;>98%;在氮气保护下,化合物B(11.7 g,70.5 mmol)溶于干燥过的THF(150 mL)中,搅拌至完全溶解。接着冷却到0℃,加入氯甲酸乙酯(15.65 mL,119.8 mmol),然后逐滴加入Et3N(22.83 mL,120.0 mmol)。待滴加完毕后,该体系在冰水浴条件下继续反应4 h。反应结束后,过滤掉Et3N·HCl,滤液经旋蒸浓缩,乙醚进行多次重结晶,得到黄色晶体含双硫五元环功能基团的环状碳酸酯单体(CDC),产率:64%。
实施例二 合成两嵌段聚合物PEG5k-P(CDC5.8k-co-TMC23k)
在氮气环境下,0.1 g(0.52 mmol)CDC单体和0.4 g(4.90 mmol)的三亚甲基碳酸酯(TMC)溶在5 mL二氯甲烷中,加入密封反应器里,然后加入0.12 g(0.02 mmol)CH3O-PEG5000 和0.5 mL的催化剂双(双三甲基硅基)胺锌的二氯甲烷溶液(0.1 mol/L),接着把反应器密封好,转移出手套箱, 40 ℃油浴中反应2天后,冰乙酸终止反应,冰乙醚中沉淀,最终经过过滤、真空干燥得到PEG5k-P(CDC5.8k-co-TMC23k)。1H NMR (400 MHz, CDCl3):2.08 (t, -COCH2 CH 2 CH2O-), 3.08(s, -CCH2), 3.30(m,-OCH3),3.65(-OCH 2 CH 2 O-),4.28(t, -COCH2CH2 CH 2 O-), 4.31 (m, -CCH2)。核磁计算出下式中k=114,x=30.2,y=225.5。GPC测分子量:45.6 kDa,分子量分布:1.53。
实施例三 合成两嵌段聚合物Mal-PEG6k-P(CDC4.8k-co-TMC19.2k)
在氮气环境下,0.1 g(0.52 mmol)CDC单体和0.4 g(3.85 mmol)的TMC溶在3 mL二氯甲烷中,加入密封反应器里,然后加入0.12 g(0.02 mmol)Mal-PEG6000和0.1 mol/L的催化剂双(双三甲基硅基)胺锌的二氯甲烷溶液(0.1 mol/L),接着把反应器密封好,转移出手套箱, 40 ℃油浴反应2天后,冰乙酸终止反应,冰乙醚中沉淀,最终经过过滤、真空干燥得到Mal-PEG6k-P(CDC4.8k-co-TMC19.2k)。1H NMR (400 MHz, CDCl3): 2.08 (t, -COCH2 CH 2 CH2O-), 3.08 (s, -CCH2), 3.30 (m,-OCH3),3.65 (t,-OCH 2 CH2O-),4.28 (t, -COCH2CH2 CH 2 O-), 4.31 (m, -CCH2),和6.70(s,Mal)。核磁计算出下式中,k=136,x=25,y=188。GPC测的分子量:38.6 kDa,分子量分布:1.42。
实施例四 合成两嵌段聚合物NHS-PEG6.5k-P(CDC6k-co-TMC22.6k)
在氮气环境下,0.1 g(0.52 mmol)CDC单体和0.42 g(4.12 mmol)的TMC溶在5 mL二氯甲烷中,加入密封反应器里,然后加入0.11 g(0.017 mmol)NHS-PEG6500和0.5 mL的催化剂双(双三甲基硅基)胺锌的二氯甲烷溶液(0.1 mol/L),接着把反应器密封好,转移出手套箱, 40 ℃油浴反应2天后,冰乙酸终止反应,冰乙醚中沉淀,最终经过过滤、真空干燥得到NHS-PEG6.5k-P(CDC6k-co-TMC22.6k)。1H NMR (400 MHz, CDCl3): 2.08 (t, -COCH2 CH 2 CH2O-), 3.08 (s, -CCH2), 3.30 (m,-OCH3),3.65(-OCH 2 CH2O-),4.28 (t, -COCH2CH2 CH 2 O-), 4.31 (m, -CCH2),和2.3(s,NHS)。核磁计算出下式中k=148,x=31.3,y=221.6。GPC测分子量:51.3 kDa,分子量分布:1.43。
实施例五 合成两嵌段聚合物PEG7.5k-P(CDC5.8k-co-TMC20.0k)
在氮气环境下,60 mg(0.31 mmol)CDC单体和0.2 g(1.93 mmol)的TMC溶在1 mL二氯甲烷中,加入密封反应器里,然后加入75 mg(0.01 mmol)CH3O-PEG7500和0.5 mL的催化剂双(双三甲基硅基)胺锌的二氯甲烷溶液(0.1 mol/L),40 ℃油浴反应2天,后处理同实施例二,得到PEG7.5k-P(CDC5.8k-co-TMC20.0k)。反应式和1H NMR特征峰同实施例二。核磁计算出式中k=170,x=30,y=196。GPC测分子量:54.5 kDa,分子量分布:1.36。
实施例六 合成两嵌段聚合物PEG5k-P(CDC3.9k-co-LA18.0k)
在氮气环境下,0.08 g(0.42 mmol)CDC和0.3 g(2.1 mmol)的丙交酯(LA)溶在2mL二氯甲烷中,加入密封反应器里,然后加入0.1 g(0.02 mmol)CH3O-PEG5000 和0.1 mol/L的催化剂双(双三甲基硅基)胺锌的二氯甲烷溶液(0.1 mL),40℃油浴反应2天,后处理同实施例二,得到PEG5k-P(CDC3.9k-co-LA14.6k)。1H NMR (400 MHz, CDCl3): 1.,59 (s, -COCH(CH 3 ) O-), 3.08 (s, -CCH2), 3.30 (m,-OCH3),3.65(-OCH 2 CH2O-),4.31 (m, -CCH2),5.07 (s, -COCH(CH3) O-)。核磁计算下式中,k=114,x=20,y=125。GPC测分子量:34.3kDa,分子量分布:1.32。
实施例七 合成两嵌段聚合物PEG6.5k-P(CDC5.8k-co-LA28.3k)
在氮气环境下,0.1 g(0.57 mmol)CDC和0.5 g(3.5 mmol)的LA溶在3 mL二氯甲烷中,加入密封反应器,然后加入0.11 g(0.015 mmol)CH3O-PEG6500和0.5 mL的催化剂双(双三甲基硅基)胺锌的二氯甲烷溶液(0.1 mol/L),40 ℃油浴反应2天,后处理同实施例二,得到PEG6.5k-P(CDC5.8k-co-LA28.3k)。反应式和1H NMR特征峰同实施例六。核磁计算式中k=148,x=30,y=190。GPC分子量:42.4 kDa,分子量分布:1.43。
实施例八 合成两嵌段聚合物Mal-PEG6k-P(CDC3.6k-co-LA18.6k)
在氮气环境下,0.1 g(0.52 mmol)CDC和0.5 g(5.56 mmol)的LA溶在4 mL二氯甲烷中,加入密封反应器里,然后加入0.15 g(0.025 mmol)Mal-PEG6000 和0.1 mol/L的催化剂双(双三甲基硅基)胺锌的二氯甲烷溶液(0.1 mL)40 ℃油浴反应2天,后处理同实施例二,得到Mal-PEG6k-P(CDC3.6k-co-LA18.6k)。1H NMR (400 MHz, CDCl3): 1.59 (s, -COCH(CH 3 ) O-), 3.08 (s, -CCH2), 3.30 (m,-OCH3),3.65 (t,-OCH 2 CH2O-),4.31 (m, -CCH2),5.07 (s, -COCH(CH3) O-),和6.70(s,Mal)。核磁计算出下式中k=136,x=20,y=129。GPC测分子量:32.5 kDa,分子量分布:1.44。
实施例九 合成三嵌段聚合物P(CDC3.8k-co-TMC18.8k)-PEG10k-P(CDC3.8k-co-TMC18.8k)
在氮气环境下0.8 g(7.84 mmol)的TMC和0.16 g(0.83 mmol)CDC溶在8 mL二氯甲烷中,加入密封反应器里,后加入0.2 g(0.04 mmol)的HO-PEG-OH10000和1 mL的催化剂双(双三甲基硅基)胺锌的二氯甲烷溶液(0.2 mol/L),40 ℃油浴反应2天,后处理同实施例二,得到三嵌段聚合物P(CDC3.8k-co-TMC18.8k)-PEG10k-P(CDC3.8k-co-TMC18.8k)。1HNMR特征峰同实施例二。核磁计算出下式中,m=227,x=20,y=184。GPC测的分子量:92.3 kDa,分子量分布:1.46。
实施例十 合成两嵌段聚合物NHS-PEG7.5k-P(CDC3.8k-co-LA13.8k)
在氮气环境下,0.1 g(0.52 mmol)CDC和0.4 g(2.8 mmol)的LA溶在3 mL二氯甲烷中,加入密封反应器里,然后加入0.013 mmol的NHS-PEG7500 和1 mL的催化剂双(双三甲基硅基)胺锌的二氯甲烷溶液(0.1 mol/L),密封反应器,转移出手套箱,40 ℃油浴反应2天,后处理同实施例二,得到NHS-PEG7.5k-P(CDC4.8k-co-LA19.0k)。1H NMR (400 MHz,CDCl3): 1.,59 (s, -COCH(CH 3 ) O-), 3.08 (s, -CCH2), 3.30 (m,-OCH3),3.65 (t,-OCH 2 CH2O-),4.31 (m, -CCH2),5.07 (s, -COCH(CH3) O-)和2.3(s,NHS)。核磁计算出下式中,k=170,x=20,y=96。GPC测分子量:42.3 kDa,分子量分布:1.45。
采用上述类似的制备方法可以制备多种含双硫碳酸酯单体的聚合物,原料比例以及表征见表1。
表1 各个聚合物制备条件、产物的核磁及GPC表征结果
实施例十一 合成靶向聚合物transferrin-PEG7.5k-P(CDC3.8k-co-LA13.8k)
转铁蛋白transferrin偶联的聚合物的合成分为两步,第一步如实施例八制备Mal-PEG7.5k-P(CDC3.8k-co-LA13.8k);第二步为transferrin与其通过迈克尔反应键合。先将上述聚合物Mal-PEG7.5k-P(CDC3.8k-co-LA13.8k)溶解在DMF中,加入两倍摩尔量的transferrin,30 ℃反应两天、透析、冻干,得到transferrin-PEG6.5k-P(CDC3.8k-co-LA13.8k),通过核磁和BCA蛋白试剂盒测试计算transferrin接枝率为95%。
实施例十二 合成靶向聚合物Herceptin-PEG6k-P(CDC3.6k-co-LA18.6k)
人类表皮生长因子抗体Herceptin偶联的聚合物的合成分为三步,第一步如实施例八制备Mal-PEG6k-P(CDC3.6k-co-LA18.6k);第二步Mal-PEG6k-P(CDC3.6k-co-LA18.6k)与半胱胺迈克尔加成反应,使得端基转变为氨基;第三步FA的羧基与其通过酰胺化反应键合:先将前步得到的聚合物溶在0.5毫升DMF中,加入2毫升的硼酸缓冲溶液(pH 8.0),再加入2倍摩尔量的Herceptin,30 ℃反应两天,透析、冷冻干燥得到最终产物Herceptin-PEG6k-P(CDC3.6k-co-LA18.6k),核磁和BCA蛋白测试计算FA接枝率为96%。
实施例十三 合成靶向聚合物FA-PEG6.5k-P(CDC6k-co-TMC22.6k)
叶酸 (FA) 偶联的聚合物的合成分为两步,第一步如实施例四制备NHS-PEG6.5k-P(CDC6k-co-TMC22.6k);第二步FA的氨基与其通过酰胺化反应键合:先将上述聚合物溶解在DMF中,加入两倍摩尔量的FA,30 ℃反应两天后,透析除去游离FA,冷冻干燥得到FA-PEG6.5k-P(CDC6k-co-TMC22.6k),通过核磁测试计算FA接枝率为88%。
实施例十四 合成靶向聚合物GE11-PEG6.5k-P(CDC6k-co-TMC22.6k)
环状多肽YHWYGYTPQNVI(GE11)偶联的聚合物的合成分为两步,第一步如实施例四制备NHS-PEG6.5k-P(CDC6k-co-TMC22.6k);第二步为GE11 的氨基与其通过酰胺化反应键合:先将上述聚合物溶在DMF中,加入两倍摩尔量的GE11,30 ℃反应两天后,透析除去游离GE11,冷冻干燥得到GE11-PEG6.5k-P(CDC6k-co-TMC22.6k),通过核磁和BCA蛋白试剂盒计算GE11接枝率为96%。
根据实施例十一至实施例十三的方法,可以在实施例二至实施例十以及表1的含双硫碳酸酯单体的聚合物键合靶向分子制备得到卵巢癌特异靶向的生物可降解双亲性聚合物。
实施例十五 制备自交联聚合物囊泡
采用溶剂置换法制备聚合物囊泡。100 μL的PEG5k-P(CDC5.8k-co-TMC23k)的DMF溶液(10 mg/mL)滴加到900 μL磷酸盐缓冲溶液(PB,10 mM,pH 7.4)中,在37 ℃(200 rmp)摇床中放置过夜进行自交联,然后装入透析袋(MWCO 7000)中透析过夜,换五次介质PB。图1是上述自交联囊泡PEG5k-P(CDC5.8k-co-TMC23k)粒径分布(A)及电子透射显微镜图片(B),交联囊泡稳定性的测试(C)及还原响应性测试(D)图;得到的自交联囊泡的尺寸由动态光散射粒度分析仪(DLS)测的形成的纳米囊泡为 130 nm,粒径分布很窄,见图1中A;由图1中B可知,TEM测得纳米粒子为中空的囊泡结构,自交联囊泡在高倍稀释和胎牛血清存在下仍然保持不变的粒径和粒径分布(图1中C),但在模拟肿瘤细胞还原环境下快速释放,解交联(图1中D)。由此可知,得到的囊泡可自交联,并具有还原敏感的解交联的性质。采用相同的制备方法,PEG5k-P(CDC4.9k-co-TMC19k)可形成自交联纳米囊泡,粒径为100 nm,粒径分布为0.1。
实施例十六 采用透析法和薄膜水化法制备自交联聚合物囊泡
采用透析法制备自交联聚合物囊泡。100 μL的PEG5k-P(CDC5.8k-co-TMC23k)的DMF溶液(10 mg/mL)装入透析袋(MWCO 7000)中,在PB中、37 ℃(200 rmp) 摇床中放置过夜自行交联,然后PB中透析24小时,换五次液。DLS测交联囊泡为 60 nm左右,粒径分布0.08。
采用薄膜水化法制备自交联聚合物囊泡。2 mg的PEG5k-P(CDC5.8k-co-TMC23k)的溶于0.5 mL的低沸点有机溶剂中,如二氯甲烷或乙腈中,在25毫升的尖底烧瓶中,旋蒸在底部形成薄膜,然后再0.1 mBar的真空度下继续抽干24小时。 加入2 mL的PB(10 mM,pH 7.4)在37 ℃下搅拌把薄膜剥离表面,并搅碎,超声20分钟 (200 rmp),不断搅拌24小时,得到的囊泡自行交联。DLS测定自交联囊泡的尺寸为 160 nm左右,粒径分布0.24。
实施例十七 制备基于PEG5k-P(CDC5.8k-co-TMC23k)和GE11-PEG6.5k-P(CDC6k-co-TMC22.6k)的自交联聚合物囊泡GE11-CLPs
实施例十四中得到的靶向聚合物GE11-PEG6.5k-P(CDC6k-co-TMC22.6k)和实施例二得到的PEG5k-P(CDC5.8k-co-TMC23k)二者混合溶于DMF中,采用如实施例十五的溶剂置换法制备自交联聚合物囊泡。靶向聚合物的PEG分子量比非靶向的PEG要长,保证靶向分子更好的支出表面。两者按不同比例混合可制备表面具有不同靶向分子含量的自交联聚合物囊泡GE11-CLPs。本实施例靶向聚合物GE11-PEG6.5k-P(CDC6k-co-TMC22.6k)的用量为10~30 wt.%。DLS测定制备的自交联聚合物囊泡尺寸为85-130 nm左右,粒径分布0.01-0.20。
实施例十八 制备基于FA-PEG6.5k-P(CDC6k-co-TMC22.6k)和PEG5k-P(CDC5.8k-co-TMC23k)的自交联聚合物囊泡FA-CLPs
1.6 mg的实施例二得到的PEG5k-P(CDC5.8k-co-TMC23k)的DMF溶液(10 mg/mL)及0.4 mg的实施例十三中得到的FA-PEG6.5k-P(CDC6k-co-TMC22.6k) 溶于0.5 mL的低沸点有机溶剂中,如二氯甲烷或乙腈中,采用如实施例十七的薄膜水化法制备得到的自交联聚合物囊泡为 88 nm左右,粒径分布0.08。两者按不同比例混合可制备表面具有不同靶向分子含量的自交联囊泡FA-CLPs。FA-PEG6.5k-P(CDC6k-co-TMC22.6k)的用量为5~30 wt.%,制备的自交联聚合物囊泡尺寸为85~130 nm左右,粒径分布0.01~0.20。
实施例十九 制备表面偶联transferrin的自交联囊泡transferrin-CLPs
实施例八制备的Mal-PEG6k-P(CDC3.6k-LA18.6k)和P(CDC3.8k-LA18.8k)-PEG4k-P(CDC3.8k-LA18.8k)混合,然后加入0.5毫升的4M硼酸缓冲溶液(pH 8.0)调节溶液pH至7.5-8.0,再按照Mal摩尔量的1.5倍加入transferrin,通过迈克尔加成反应键合,30 ℃反应两天后,透析,按照实施例十六所述透析方法制备囊泡transferrin-CLPs。DLS测定为115 nm,粒径分布0.12。核磁和BCA蛋白试剂盒测试计算多肽的接枝率为94%。靶向聚合物与非靶向聚合物在制备囊泡过程中按照质量比百分数投料,可获得不同靶向分子的自交联囊泡transferrin-CLPs,尺寸为85-130 nm左右,粒径分布0.01-0.20。
采用上述类似的制备方法可以制备多种自交联聚合物囊泡,原料比例以及表征见表2。
表2 自交联聚合物囊泡的制备和表征
。
实施例二十 自交联聚合物囊泡的药物装载及体外释放
采用溶剂置换法制备PEG5k-P(CDC5.8k-co-TMC23k) 自交联聚合物囊泡,DOX·HCl的装载采用pH梯度法,利用囊泡内外pH的不同来包裹亲水药物DOX·HCl。100 μL的PEG5k-P(CDC5.8k-co-TMC23k)的DMF溶液(10 mg/mL)滴加到900 μL柠檬酸钠/柠檬酸缓冲溶液(10 mM,pH 4.0)中,在37 ℃ (200 rmp) 摇床中放置5小时,然后加入0.05 mL的PB(4M,pH 8.1)建立pH梯度,随后立即加入DOX·HCl,摇床中放置5-10小时允许药物进入囊泡中,同时自交联。最后装入透析袋(MWCO 7000)中透析过夜,换五次水,透析介质为PB(10mM,pH 7.4)。载不同比例的药(10%-30%)的自交联囊泡的粒径在108-128 nm,粒径分布在0.10-0.14。荧光光谱仪测定DOX·HCl的包裹效率为68%-85%。DOX·HCl的体外释放实验是在37 ℃恒温摇床中震荡(200 rpm)进行,每组各有三个平行样。第一组,载DOX·HCl的自交联囊泡在加入10 mM GSH模拟细胞内还原环境PB (10 mM, pH 7.4) 中;第二组,载DOX·HCl的自交联囊泡在PB (10 mM, pH 7.4);载药自交联囊泡的浓度为30 mg/L,取0.6 mL 放入透析袋(MWCO: 12,000)中,每个试管中加入相应的透析溶剂25 mL,在预定的时间间隔,取出5.0 mL透析袋外部介质用作测试,同时向试管中补加5.0 mL 相应介质。使用荧光仪测定溶液中药物浓度。附图2为DOX·HCl累积释放量与时间的关系,从图中可以看出,加入模拟肿瘤细胞内GSH后,其释放明显要快于没加GSH的样本,说明载药自交联囊泡在10 mM的GSH的存在下,能有效释放药物。
采用和上述相同的方法制备了装载DOX·HCl的自交联聚合物囊泡PEG5k-P(CDC4.9k-co-TMC19k)。载不同比例的药(10%~30%)的自交联囊泡的粒径在100-125 nm,粒径分布在0.10-0.14。荧光光谱仪测定DOX·HCl的包裹效率为60%~80%。
用溶剂置换法制备Ally-PEG6k-P(CDC2.9k-CL14.2k) 自交联聚合物囊泡。10 µL的紫杉醇PTX的DMF溶液 (10 mg/mL)和90 μL的Ally-PEG6k-P(CDC2.9k-CL14.2k)的DMF溶液(10 mg/mL)混合,然后滴加到900 μL磷酸盐缓冲溶液(10 mM,pH 7.4,PB)中,在37 ℃(200 rmp) 摇床中放置过夜进行自交联,然后装入透析袋(MWCO 7000)中透析过夜,换五次水,透析介质为PB(10 mM,pH 7.4)。PTX的含量在0-20 wt.%,得到的自交联囊泡尺寸为 130-170 nm,粒径分布0.1-0.2。TEM测得为囊泡结构,具有还原敏感的解交联性质。PTX的包裹效率为50%-70%)。体外释放实验设计同上,加GSH后疏水药物释放明显要快于没加GSH样本。
用薄膜水化法制备载药的基于PEG6.5k-P(CDC6k-co-TMC22.6k) 的自交联聚合物囊泡FA-CLPs,pH梯度法装载DOX·HCl。1.6 mg的PEG5k-P(CDC5.8k-co-TMC23k)及0.4 mg的FA-PEG6.5k-P(CDC6k-co-TMC22.6k) 溶于0.5 mL的低沸点有机溶剂中,如二氯甲烷或乙腈中,在25毫升的尖底烧瓶中,旋蒸在底部形成薄膜,然后再0.1 mBar的真空度下继续抽干24小时。加入2 mL柠檬酸钠/柠檬酸缓冲溶液(10 mM,pH4.0)中,在37 ℃下搅拌把薄膜剥离表面,并搅碎,超声20分钟 (200 rmp),不断搅拌24小时,自交联。DLS测定交联囊泡的尺寸为90 nm左右,粒径分布0.10。在上述囊泡溶液中加入0.05 mL的PB(4M,pH8.1)建立pH梯度,随后立即加入DOX·HCl,摇床中放置5-10小时。然后装入透析袋(MWCO 7000)中对PB透析过夜,换五次液。载不同比例药量(10%-30%)之后,粒径112-121 nm,粒径分布0.10-0.15,DOX·HCl的包裹效率61%-77%。体外释放实验设计同上,加入10mM GSH后,药物有效释放,速度明显要快于没加GSH的样本。
采用透析法制备载药的基于PEG6.5k-P(CDC6k-co-TMC22.6k)的自交联聚合物囊泡GE11-CLPs,pH梯度法装载盐酸阿霉素(Epi·HCl)。80 μL的PEG5k-P(CDC5.8k-co-TMC23k)的DMF溶液(10 mg/mL)及20 μL的GE11- PEG6.5k-P(CDC6k-co-TMC22.6k)的DMF溶液(10 mg/mL)均匀混合之后,直接装入透析袋(MWCO 7000)中,在柠檬酸钠/柠檬酸缓冲溶液(10 mM,pH4.0)中,在37 ℃ 摇床中放置4小时自交联,后对相同的介质透析12小时,换五次液。DLS测交联囊泡为 96 nm,粒径分布0.18。在上述囊泡溶液中加入0.05 mL的PB(4M,pH8.5)建立pH梯度,随后立即加入Epi·HCl,摇床中放置5-10小时。然后装入透析袋(MWCO7000)中对PB透析过夜,换五次液。载不同比例药(10%-30%),粒径98-118 nm,粒径分布0.10-0.15,DOX·HCl的包裹效率为64%-79%。Epi·HCl体外释放实验设计同上,见图3,加入10mM GSH后,药物有效释放,速度明显要快于没加GSH的样本。
采用上述类似的制备方法可以研究多种自交联聚合物囊泡和靶向自交联聚合物囊泡对多种亲水抗癌小分子药物及基因如盐酸多柔比星(DOX·HCl)、盐酸表阿霉素(Epi·HCl)、盐酸伊利替康(CPT·HCl)和盐酸米托蒽醌(MTO·HCl)以及疏水抗癌药物紫杉醇、多烯紫杉醇和奥拉帕尼的载药量和包封率,见表3。
表3 自交联聚合物囊泡和靶向自交联聚合物囊泡载亲水药物的载药量、包封率
。
实施例二十一 MTT法测试空自交联聚合物囊泡对SKOV3细胞的毒性
采用MTT法测试空囊泡的细胞毒性,使用SKOV3人卵巢癌细胞。以5×104个/mL将SKOV3细胞种于96孔板,每孔100 μL,24小时后养至细胞贴壁70%左右。然后,实验组各孔中分别加入含有不同浓度(0.5,1.0 mg/mL)的囊泡样品(以实施例十五和实施例十九的空的自交联聚合物囊泡为例),另设细胞空白对照孔和培养基空白孔(复4孔)。培养24小时后,每孔加入MTT(5.0 mg/mL)10 μL,继续培养4小时后每孔加入150 μL DMSO溶解生成的结晶子,用酶标仪于492 nm处测吸光度值(A),以培养基空白孔调零,计算细胞存活率。附图4为自交联聚合物囊泡的细胞毒性结果,可看出,当自交联聚合物囊泡的浓度从0.5增到1.0 mg/mL时,SKOV3的存活率仍高于92%,说明本发明的自交联聚合物囊泡具有良好的生物相容性。
实施例二十二 MTT法测载药自交联囊泡对SKOV3卵巢癌细胞的毒性
细胞的培养和实施例二十一相同,只是实验组各孔加样时,载DOX·HCl的PEG5k-P(CDC5.8k-co-TMC23k) 自交联聚合物囊泡、载DOX·HCl的由PEG5k-P(CDC5.8k-co-TMC23k)和GE11-PEG6.5k-P(CDC6k-co-TMC22.6k)构成的自交联聚合物囊泡GE11-CLPs(其中GE11含量分别为10%、20%、30%)加入各对应孔中,DOX·HCl浓度范围为0.01、0.1、0.5、1、5、10、20、40 和80 μg/mL;靶向分子含量从10%、20%到30%;阿霉素脂质体里葆多组作为对照组。共同培养4小时后,吸出样品换上新鲜培养基继续孵育44 h后。而后的MTT加入、处理和测定吸光度同实施例二十一。附图5和图6 是载药自交联聚合物囊泡GE11-CLPsGE11/对SKOV3细胞的毒性;可看出,载DOX·HCl的20% GE11-CLPsGE11自交联聚合物囊泡对SKOV3细胞的半致死浓度(IC50)为2.01 μg/mL,远远低于PEG5k-P(CDC5.8k-co-TMC23k) 自交联聚合物囊泡,也低于阿霉素脂质体里葆多(14.23 μg/mL),说明本发明的载药靶向自交联囊泡能有效靶向到卵巢癌细胞,在细胞内释放药物,最终杀死癌细胞。
实施例二十三 MTT法测试载药自交联聚合物囊泡对A2780细胞的毒性
细胞的培养和实施例二十一相同,只是实验组各孔加样时,针对不同transferrin含量、不同药量的载药自交联聚合物囊泡,以载CPT·HCl、由Mal-PEG6k-P(CDC3.6k-LA18.6k)和P(CDC3.8k-LA18.8k)-PEG4k-P(CDC3.8k-LA18.8k) 制备的自交联聚合物囊泡transferrin-CLPs(实施例十九)为例,加入各对应孔中,CPT·HCl浓度范围为0.01、0.1、0.5、1、5、10、20和40 μg/mL;靶向分子含量从10%、20%到30%;P(CDC3.8k-LA18.8k)-PEG4k-P(CDC3.8k-LA18.8k)载药交联聚合物囊泡和游离CPT·HCl组作为对照组。共同培养4小时后,吸出样品换上新鲜培养基继续孵育44 h后。而后的MTT加入、处理和测定吸光度同实施例二十一。结果表明,P(CDC3.8k-LA18.8k)-PEG4k-P(CDC3.8k-LA18.8k)载药自交联聚合物囊泡对A2780细胞的IC50为4.15 μg/mL,特别是载CPT·HCl的30% transferrin-CLPs对A2780细胞的IC50为2.07 μg/mL,低于自由药物CPT·HCl(4.11 μg/mL)。
说明本发明的载药自交联聚合物囊泡能有效靶向到卵巢癌细胞,并在细胞内释放药物,最终杀死癌细胞,尤其是键合靶向分子后,极大增强了对卵巢癌细胞的特异性,显著提高了药物对卵巢癌细胞的杀伤力。
采用上述类似的方法研究了多种载药自交联聚合物囊泡对卵巢癌细胞的毒性,药物为亲水抗癌小分子药物及基因药物为盐酸多柔比星(DOX·HCl)、盐酸表阿霉素(Epi·HCl)、盐酸伊利替康(CPT·HCl)和盐酸米托蒽醌(MTO·HCl) 以及疏水抗癌药物紫杉醇、多烯紫杉醇和奥拉帕尼,结果见表4。
实施例二十四 载药的自交联囊泡(CLPs及GE11-CLPs)的细胞内吞
采用流式法测试载药囊泡的细胞内吞,使用SKOV3人卵巢癌细胞。以2×105个/mL将SKOV3细胞种于6孔板,每孔900 μL,24小时后养至细胞贴壁70%左右。然后,实验组各孔中分别加入载药囊泡样品CLPs及GE11-CLPs,另设细胞空白对照孔和生理盐水对照组(复2孔)。培养4小时后,每孔加入胰酶消化五分钟,并用生理盐水洗涤三次,用流式细胞仪仪于488 nm处测阿霉素荧光吸收强度,以生理盐水组为对照,计算细胞内吞量。附图7为载药交联囊泡的细胞摄取结果,可看出,靶向载药自交联囊泡细胞摄取量高于无靶向交联囊泡及阿霉素脂质体里葆多,说明靶向自交联囊泡能主动被卵巢癌细胞摄取内吞。
实施例二十五 载药的自交联聚合物囊泡(CLPs和FA-CLPs)的血液循环
所有动物实验操作符合苏州大学动物实验中心规定。实验选用体重为18~20克,4~6周龄的Balb/C裸鼠。囊泡由FA-PEG6.5k-P(CDC6k-co-TMC22.6k)和PEG5k-P(CDC5.8k-co-TMC23k)按不同比例混合制备,命名为FA-CLPs,当FA在聚合物囊泡中的靶向比例为20%时,粒径为100纳米,粒径分布为 0.10,命名为FA20-CLPs,药物为DOX·HCl。将载DOX·HCl的CLPs囊泡、FA-CLPs囊泡和DOX·HCl通过尾静脉注射小鼠体内(DOX药量为10 mg/kg),在0、0.25、0.5、1、2、4、8、12和24 小时定点取血约10 μL,通过差量法准确计算血液重量,再加入100 μL浓度为1%的曲拉通和500 μL萃取液(DMF含20 mM的DTT和1 M的HCl);然后离心(20000转/分钟,20分钟)后,取上层清液,通过荧光测得每个时间点DOX·HCl的量。由计算可知,载药FA-CLPs自交联聚合物囊泡-和载药CLPs自交联聚合物囊泡在小鼠体内的消除半衰期分别为4.23和4.16小时,而DOX·HCl的仅为0.27小时,所以本发明公开的自交联聚合物囊泡在小鼠体内稳定,有较长循环时间。其他载药自交联聚合物囊泡的血液循环实验的操作和计算方法相同,结果在表4。
实施例二十六 载药的自交联聚合物囊泡CLPs和GE11-CLPs的血液循环
如实施例二十五,由GE11-PEG6.5k-P(CDC6k-co-TMC22.6k)和PEG5k-P(CDC5.8k-co-TMC23k)混合制备得自交联囊泡GE11-CLPs,以GE11-CLPs自交联囊泡以及自交联囊泡CLPs装载DOX·HCl后,尾静脉注射入Balb/C裸鼠中,研究其血液循环,DOX·HCl和里葆多DOX-LPs用于对照组。结果如图10所示,GE11-CLPs和CLPs囊泡在48小时后仍有5.0 ID%/g。由计算可知,GE11-CLPs自交联囊泡和CLPs自交联囊泡在小鼠体内的消除半衰期分别为4.99和4.79小时,所以其在小鼠体内稳定,有较长的循环时间。结果在表4。
实施例二十七 自交联囊泡FA-CLPs在荷SKOV3卵巢癌小鼠的活体成像
活体成像实验选用体重为18~20 克左右,4~6周龄的Balb/C裸鼠,在皮下注射5×106个SKOV3人卵巢癌细胞,大约3~4周后,肿瘤大小为100~200 mm3时开始实验。以由FA-PEG6.5k-P(CDC6k-co-TMC22.6k)和PEG5k-P(CDC5.8k-co-TMC23k)按1:5混合制备的自交联聚合物囊泡FA20-CLPs和自交联囊泡CLPs为例。将荧光物质cy-7标记的FA20-CLPs和无靶向的CLPs 通过尾静脉注射小鼠体内,然后在不同时间点1、2、4、6、8、12、24、48小时用小动物活体成像仪来追踪囊泡的去向。实验结果可知,FA20-CLPs在肿瘤部位很快积累,且在48小时后荧光仍然很强。说明FA20-CLPs能主动靶向及富集到卵巢癌肿瘤部位,对卵巢癌细胞具有极强的特异性。其他自交联聚合物囊泡的活体成像实验的操作和计算方法相同,结果在表4。
制备载 Epi·HCl 的、cy-7标记的CLPs和GE11-CLPs,活体成像实验中肿瘤的接种以及尾静脉给药同上,发现二者都可在卵巢肿瘤部位很快积累,CLPs在4-6小时消失,而GE11-CLPs在48小时后肿瘤部位荧光仍然很强,说明GE11-CLPs能主动靶向及富集到卵巢肿瘤部位。
实施例二十八 载药自交联聚合物囊泡CLPs和transferrin-CLPs在荷A2780卵巢癌小鼠的活体成像实验
活体成像实验选用体重为18~20 克左右,4~6周龄的Balb/C裸鼠,在皮下注射5×106个A2780人卵巢癌细胞,大约3~4周后,肿瘤大小为100~200 mm3时开始实验。由transferrin-PEG6.5k-P(CDC3.8k-co-LA13.8k)和PEG5k-P(CDC3.7k-co-LA14.6k) 混合制备的靶向自交联囊泡transferrin-CLPs和载药自交联囊泡CLPs用cy-5标记,装载了疏水药物多烯紫杉醇DTX,同实施例二十七操作来研究活体成像。实验结果可知,载DTX的transferrin-CLPs可在肿瘤部位很快积累,并在48小时后肿瘤部位荧光仍然很强。说明transferrin-CLPs能主动靶向及富集到肿瘤部位,而载药CLPs自交联囊泡在2小时进入肿瘤后很快代谢,且强度低。
实施例二十九 载药自交联聚合物囊泡CLPs和FA-CLPs在荷SKOV3卵巢癌小鼠的体内生物分布
样本FA20-CLPs的制备、生物分布实验中肿瘤的接种以及尾静脉给药同实施例二十七。FA20-CLPs和CLPs尾静脉注射小鼠体内(DOX·HCl:10 mg/kg),12 小时后处死老鼠,将肿瘤及心,肝,脾,肺和肾组织取出,清洗称重后加入500 μL 1%的曲拉通通过匀浆机磨碎,再加入900 μL DMF萃取(其中含有20 mM的DTT,1 M的HCl)。离心(20000转/分钟,20分钟)后,取上层清液,通过荧光测得每个时间点DOX·HCl的量。图8中横坐标为组织器官,纵坐标为每克肿瘤或组织中的DOX·HCl占总DOX·HCl注射量(ID%/g)。FA-CLPs、CLPs和DOX·HCl注射12小时在肿瘤积累的DOX·HCl量分别为6.54、2.53和 1.02 ID%/g,FA-CLPs是CLPs和DOX·HCl的3和6倍,说明载药FA-CLPs通过主动靶向在肿瘤部位积累较多,对卵巢癌细胞具有明显的特异性,有利于杀伤卵巢癌细胞,结果在表4。
实施例三十 载药自交联聚合物囊泡CLPs和GE11-CLPs在荷SKOV3卵巢癌小鼠的体内生物分布
肿瘤的接种、尾静脉给药以及动物的操作同实施例二十七。载DOX·HCl的GE11-CLPs、CLPs和脂质体阿霉素里葆多DOX-LPs尾静脉注射小鼠体内(DOX·HCl:10 mg/kg)。6小时后,GE11-CLPs、CLPs和DOX-LP在肿瘤积累的DOX·HCl量分别为8.63、3.52和 1.82ID%/g,GE11-CLPs是后两者的2和5倍,说明载药GE11CLPs通过主动靶向在肿瘤部位积累较多(图9)。
实施例三十一 载药自交联聚合物囊泡GE11-CLPs对Balb/C小鼠的最大耐受剂量(MTD)
选用体重为18~20 克左右,4~6周龄的Balb/C裸鼠。单剂量注射载药自交联聚合物囊泡GE11-CLPs及阿霉素脂质体里葆多,其中阿霉素的浓度分别为120 mg/kg、140 mg/kg、160 mg/kg、180 mg/kg及200 mg/kg, 阿霉素脂质体里葆多的浓度为20 mg/kg,每组小鼠五只,最后的10天,每天观察小鼠的精神状态及测量体重。最大耐受剂量的标准为小鼠非意外性死亡及小鼠体重低于15%。从图10中A及10中B各组分小鼠体重变化和生存率可知,载药靶向自交联囊泡的最大难受剂量为160 mg/kg,而阿霉素脂质体里葆多的最大耐受剂量为20mg/kg,由此可知,靶向性载药自交联囊泡对小鼠有很高的耐受能力,大大的提高了治疗窗口。
实施例三十二 载药自交联聚合物囊泡GE11-CLPs和CLPs在荷SKOV3皮下卵巢癌的小鼠中的抑瘤效果、体重变化和存活率
选用体重为18~20 克左右,4~6周龄的Balb/C裸鼠,在皮下注射5×106个SKOV3人卵巢癌细胞,大约两周后,肿瘤大小为30~50 mm3时开始实验。由GE11-PEG6.5k-P(CDC6k-co-TMC22.6k)和PEG5k-P(CDC5.8k-co-TMC23k)按1:5混合制备的载DOX·HCl的靶向性自交联囊泡GE11-CLPs、无靶向CLPs、DOX-LPs以及PBS尾静脉注射。由图11中可知,GE11-CLPs治疗组18天时,肿瘤得到明显抑制,而载药CLPs组肿瘤有增长,小鼠体重几乎没有改变。DOX-LPs虽然也能抑制肿瘤的增长,但DOX-LPs组的小鼠体重在12天时降低了18%,说明其对小鼠的毒副作用很大。GE11-CLPs治疗组在62天后全部存活,DOX-LPs组在42天时已全部死亡,PBS组42天时也全部死亡。因此,载药靶向自交联囊泡可有效抑制肿瘤,对小鼠没有毒副作用,可延长荷瘤老鼠的生存时间。
实施例三十三 载药靶向自交联聚合物囊泡GE11-CLPs在荷SKOV3皮下卵巢癌的小鼠中的单剂量抑瘤效果、体重变化和存活率
皮下SKOV3肿瘤模型的建立、尾静脉给药方式和数据采集同实施例三十二。载DOX·HCl的GE11-CLPs、阿霉素脂质体里葆多DOX-LPs以及PBS尾静脉单剂量注射,其中载DOX·HCl的GE11-CLPs自交联囊泡的阿霉素药量为20 mg/kg、40 mg/kg及60 mg/kg,而DOX-LPs的阿霉素浓度为10 mg/kg及15 mg/kg。由图12中可知,GE11-CLPs阿霉素浓度为60 mg/kg治疗组18天时,肿瘤得到明显抑制,而阿霉素浓度为20 mg/kg及40 mg/kg肿瘤有增长,所有组别小鼠体重几乎没有改变。DOX-LPs在阿霉素浓度为10 mg/kg及15 mg/kg单剂量都不能抑制肿瘤的增长。GE11-CLPs治疗组在49天后全部存活,DOX-LPs组在42及43天时已全部死亡,PBS组34天时也全部死亡。
实施例三十四 载药靶向自交联聚合物囊泡transferrin-CLPs 和CLPs在荷A2780皮下卵巢癌的小鼠中的抑瘤效果、体重变化和存活率
皮下A2780肿瘤模型的建立、尾静脉给药方式和数据采集同实施例三十二。肿瘤大小为30~50 mm3时开始实验,由transferrin-PEG6.5k-P(CDC3.8k-co-LA13.8k)和PEG5k-P(CDC3.7k-co-LA14.6k)按1:5混合制备装载CPT·HCl的靶向自交联囊泡transferrin-CLPs、无靶向CLPs、自由CPT·HCl 以及尾静脉注射。由cRGD-PEG6k-P(CDC4.6k-co-TMC18.6k)和PEG5k-P(CDC4.9k-co-TMC19k) 按1:5混合制备的载DOX·HCl的自交联囊泡cRGD-CLPs作为对照组。结果发现,在transferrin-CLPs治疗18天时,肿瘤得到明显抑制,而载药CLPs组肿瘤有少量增长,小鼠体重几乎没有改变。cRGD-CLPs组小鼠体重没有改变,但是肿瘤抑制明显弱于前者,肿瘤尺寸为前者的3倍,表明cRGD对卵巢癌没有明显的靶向性。CPT·HCl虽然也能抑制肿瘤的增长,但CPT·HCl组小鼠体重在10天时降低了18%。transferrin-CLPs治疗组在72天后全部存活, CPT·HCl组在28天时已全部死亡,PBS组在37天时也全部死亡。
实施例三十五 载药靶向自交联聚合物囊泡GE11-CLPs和CLPs在荷SKOV3原位卵巢癌的小鼠中的抑瘤效果、体重变化和存活率
载DOX·HCl的自交联囊泡GE11-CLPs、无靶向CLPs、DOX-LPs以及PBS尾静脉注射到荷SKOV3原位卵巢癌的小鼠中。GE11-CLPs治疗组16天内,肿瘤生物发光强度持续减弱,而载药CLP组肿瘤生物发光强度有一定增长,小鼠的体重几乎没有改变。DOX-LPs虽然也能抑制肿瘤增长,但DOX-LPs的小鼠体重在4天时降低了21%。GE11-CLPs治疗组在45天后全部存活,DOX-LPs组在32时已全部死亡,PBS组在23天时也全部死亡。因此,键合靶向分子的载药自交联囊泡GE11-CLPs可有效抑制原位卵巢癌肿瘤的增长,没有毒副作用,还可以延长荷瘤老鼠的生存时间。
采用上述类似的实验方法研究了多种载不同药物的自交联聚合物囊泡对荷卵巢癌的小鼠的影响,结果见表4。
表4 载药自交联聚合物囊泡对卵巢癌的体内外抗肿瘤结果
。
Claims (9)
1.一种卵巢癌特异靶向的生物可降解双亲性聚合物,其特征在于:所述卵巢癌特异靶向的生物可降解双亲性聚合物由含双硫碳酸酯单体的聚合物键合靶向分子制备得到;所述靶向分子为GE11多肽、叶酸FA、转铁蛋白或者Herceptin蛋白;所述含双硫碳酸酯单体的聚合物的化学结构式为式Ⅰ或者式Ⅱ中的一种:
式Ⅰ
式Ⅱ
其中, R1选自以下基团中的一种:
R2选自以下基团中的一种:
;
其中,k为113~170,x为15~45,y 为80~300,m 为220~280;
当含双硫碳酸酯单体的聚合物的化学结构式为式Ⅰ时,分子量为30~55 kDa;当含双硫碳酸酯单体的聚合物的化学结构式为式Ⅱ时,分子量为60~95 kDa。
2.一种聚合物囊泡,其特征在于,所述聚合物囊泡由以下聚合物制备得到:
(1)由权利要求1所述卵巢癌特异靶向的生物可降解双亲性聚合物制备得到;
(2)由权利要求1所述含双硫碳酸酯单体的聚合物制备得到;
(3)由权利要求1所述卵巢癌特异靶向的生物可降解双亲性聚合物与含双硫碳酸酯单体的聚合物制备得到;
(4)在权利要求1所述含双硫碳酸酯单体的聚合物制备的囊泡表面偶联靶向分子后得到,所述靶向分子为GE11多肽、叶酸、转铁蛋白或者Herceptin蛋白。
3.根据权利要求2所述聚合物囊泡,其特征在于:所述聚合物囊泡为自交联聚合物囊泡;所述自交联聚合物囊泡的粒径为50~160纳米。
4. 根据权利要求3所述聚合物囊泡,其特征在于:所述聚合物囊泡由权利要求1所述卵巢癌特异靶向的生物可降解双亲性聚合物与含双硫碳酸酯单体的聚合物制备得到;按质量百分数,所述卵巢癌特异靶向的生物可降解双亲性聚合物的用量为1~40 wt.%。
5.权利要求2~4所述任意一种聚合物囊泡作为治疗卵巢癌药物的载体的应用。
6.根据权利要求5所述的应用,其特征在于:所述治疗卵巢癌药物为小分子抗癌药物。
7.根据权利要求6所述的应用,其特征在于:所述小分子抗癌药物为紫杉醇、多西紫杉醇、阿霉素、奥拉帕尼、吉非替尼、盐酸多柔比星、盐酸表阿霉素或者盐酸伊利替康。
8.权利要求1所述的卵巢癌特异靶向的生物可降解双亲性聚合物在制备治疗卵巢癌的纳米药物中的应用。
9.权利要求2所述聚合物囊泡在制备治疗卵巢癌的纳米药物中的应用。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610123977.1A CN105669964B (zh) | 2016-03-04 | 2016-03-04 | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 |
EP17759282.1A EP3421519B1 (en) | 2016-03-04 | 2017-03-03 | Ovarian cancer specifically targeted biodegradable amphiphilic polymer, polymer vesicle prepared thereby and use thereof |
JP2018565450A JP6677914B2 (ja) | 2016-03-04 | 2017-03-03 | 卵巣癌用の特異的に標的化された生分解性両親媒性ポリマー、それから製造されたポリマーベシクル及びその使用 |
CA3016655A CA3016655C (en) | 2016-03-04 | 2017-03-03 | Ovarian cancer specifically targeted biodegradable amphiphilic polymer, polymer vesicle prepared thereby and use thereof |
PCT/CN2017/075529 WO2017148431A1 (zh) | 2016-03-04 | 2017-03-03 | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 |
KR1020187028348A KR102190093B1 (ko) | 2016-03-04 | 2017-03-03 | 난소암을 특이적으로 표적하는 생분해성 양친성 폴리머, 이로부터 제조된 폴리머 배시클 및 용도 |
AU2017226517A AU2017226517B2 (en) | 2016-03-04 | 2017-03-03 | Ovarian cancer specifically targeted biodegradable amphiphilic polymer, polymer vesicle prepared thereby and use thereof |
US16/121,606 US20180360766A1 (en) | 2016-03-04 | 2018-09-04 | Ovarian cancer specifically targeted biodegradable amphiphilic polymer, polymer vesicle prepared thereby and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610123977.1A CN105669964B (zh) | 2016-03-04 | 2016-03-04 | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105669964A CN105669964A (zh) | 2016-06-15 |
CN105669964B true CN105669964B (zh) | 2017-11-21 |
Family
ID=56307950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610123977.1A Active CN105669964B (zh) | 2016-03-04 | 2016-03-04 | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20180360766A1 (zh) |
EP (1) | EP3421519B1 (zh) |
JP (1) | JP6677914B2 (zh) |
KR (1) | KR102190093B1 (zh) |
CN (1) | CN105669964B (zh) |
AU (1) | AU2017226517B2 (zh) |
CA (1) | CA3016655C (zh) |
WO (1) | WO2017148431A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105669964B (zh) * | 2016-03-04 | 2017-11-21 | 博瑞生物医药(苏州)股份有限公司 | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 |
WO2018001256A1 (zh) * | 2016-06-30 | 2018-01-04 | 苏州大学 | 具有不对称膜结构的可逆交联聚合物囊泡、抗肿瘤药物及其制备方法 |
CN106177975B (zh) * | 2016-06-30 | 2019-01-18 | 苏州大学 | 具有不对称膜结构的可逆交联生物可降解聚合物囊泡及其制备方法与在核酸药物中的应用 |
CN106137968B (zh) * | 2016-07-15 | 2019-03-01 | 苏州大学 | 内膜具有正电的可逆交联生物可降解聚合物囊泡及其制备方法与在制备抗肿瘤药物中的应用 |
CN109771658B (zh) * | 2017-11-14 | 2021-12-10 | 博瑞生物医药(苏州)股份有限公司 | 靶向多臂偶联物 |
CN112442180B (zh) * | 2019-09-04 | 2022-04-01 | 北京化工大学 | 一种用于促进干细胞界面粘附生长的双亲性聚合物及其制备方法和用途 |
GB2597707A (en) * | 2020-07-30 | 2022-02-09 | Toxinvent Ou | Targeted anthracycline delivery system for cancer treatment |
KR20230041901A (ko) * | 2021-09-17 | 2023-03-27 | 고려대학교 산학협력단 | 신규 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1502332A (zh) * | 2002-11-25 | 2004-06-09 | 刘云清 | 抗癌药紫杉醇自乳化固体纳米粒——注射用紫杉醇的制备方法 |
CN101239041A (zh) * | 2008-03-18 | 2008-08-13 | 天津大学 | 一种高分子脂质体及其应用 |
CN104031248A (zh) * | 2014-05-28 | 2014-09-10 | 苏州大学 | 侧链含双硫五元环功能基团的碳酸酯聚合物及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040220086A1 (en) * | 2001-10-17 | 2004-11-04 | Faulk W. Page | Methods and materials for targeting and affecting selected cells |
GB0419627D0 (en) * | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
JP2010126533A (ja) * | 2008-11-28 | 2010-06-10 | Bio Verde:Kk | 高機能化抗癌剤 |
CA2748125A1 (en) * | 2008-12-22 | 2010-07-01 | Alexander Levitzki | Egfr-homing double-stranded rna vector for systemic cancer treatment |
GB201215289D0 (en) * | 2012-08-28 | 2012-10-10 | Medical Res Council | Nanoparticle formulation |
EP2956485A2 (en) * | 2013-02-13 | 2015-12-23 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-her2 antibodies and uses thereof |
CN104004001B (zh) * | 2014-05-28 | 2016-03-30 | 苏州大学 | 含双硫五元环功能基团的环状碳酸酯单体及其制备方法 |
CN104672199B (zh) * | 2015-02-13 | 2017-11-03 | 苏州大学 | 一种含双碘环碳酸酯化合物及其制备方法 |
CN105542141B (zh) * | 2015-02-13 | 2018-01-19 | 苏州大学 | 一种侧链含双碘功能基团的生物可降解共聚物及其应用 |
CN106905519B (zh) * | 2015-12-22 | 2019-07-12 | 博瑞生物医药(苏州)股份有限公司 | 生物可降解双亲性聚合物、由其制备的聚合物囊泡及在制备肺癌靶向治疗药物中的应用 |
CN105669964B (zh) * | 2016-03-04 | 2017-11-21 | 博瑞生物医药(苏州)股份有限公司 | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 |
-
2016
- 2016-03-04 CN CN201610123977.1A patent/CN105669964B/zh active Active
-
2017
- 2017-03-03 CA CA3016655A patent/CA3016655C/en active Active
- 2017-03-03 AU AU2017226517A patent/AU2017226517B2/en active Active
- 2017-03-03 EP EP17759282.1A patent/EP3421519B1/en active Active
- 2017-03-03 WO PCT/CN2017/075529 patent/WO2017148431A1/zh active Application Filing
- 2017-03-03 KR KR1020187028348A patent/KR102190093B1/ko active IP Right Grant
- 2017-03-03 JP JP2018565450A patent/JP6677914B2/ja active Active
-
2018
- 2018-09-04 US US16/121,606 patent/US20180360766A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1502332A (zh) * | 2002-11-25 | 2004-06-09 | 刘云清 | 抗癌药紫杉醇自乳化固体纳米粒——注射用紫杉醇的制备方法 |
CN101239041A (zh) * | 2008-03-18 | 2008-08-13 | 天津大学 | 一种高分子脂质体及其应用 |
CN104031248A (zh) * | 2014-05-28 | 2014-09-10 | 苏州大学 | 侧链含双硫五元环功能基团的碳酸酯聚合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
KR102190093B1 (ko) | 2020-12-14 |
EP3421519B1 (en) | 2020-10-21 |
JP2019507190A (ja) | 2019-03-14 |
CA3016655A1 (en) | 2017-09-08 |
JP6677914B2 (ja) | 2020-04-08 |
AU2017226517B2 (en) | 2019-09-12 |
CN105669964A (zh) | 2016-06-15 |
WO2017148431A1 (zh) | 2017-09-08 |
CA3016655C (en) | 2020-12-29 |
EP3421519A4 (en) | 2019-03-13 |
AU2017226517A1 (en) | 2018-10-11 |
EP3421519A1 (en) | 2019-01-02 |
KR20180120220A (ko) | 2018-11-05 |
US20180360766A1 (en) | 2018-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105669964B (zh) | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 | |
CN106905519B (zh) | 生物可降解双亲性聚合物、由其制备的聚合物囊泡及在制备肺癌靶向治疗药物中的应用 | |
CN103705943B (zh) | 一种还原响应型聚乙二醇化药物纳米组合物的制备及其应用 | |
CN106265510A (zh) | 一种肿瘤细胞内pH触发式释药的多级靶向聚合物胶束及其制备方法 | |
CN108559091A (zh) | 具有聚集诱导发光及双重敏感性的聚合物药物载体、载药胶束及其制备方法 | |
CN105859990B (zh) | 侧链含硫辛酰基的聚合物、其制备方法及由其制备的聚合物囊泡及其应用 | |
CN107998082A (zh) | 一种还原响应聚合物囊泡纳米药物在制备脑肿瘤治疗药物中的应用 | |
CN105860057B (zh) | 基于疏水功能性小分子‑亲水聚氨基酸的生物可降解聚合物及其制备方法和应用 | |
CN108659232A (zh) | 半固态酸敏感两亲性嵌段共聚物与制备方法及其用途 | |
CN105001426B (zh) | 一种具有肿瘤靶向性的聚氨基酸接枝共聚物及其制备方法 | |
CN107266384B (zh) | 基于2-氨基十六烷酸的n-羧基内酸酐单体和聚氨基酸及其制备方法 | |
CN108126210A (zh) | 一种单靶向还原响应囊泡纳米药物在制备脑肿瘤治疗药物中的应用 | |
CN104784700B (zh) | 一种药物共载复合物、胶束及胶束的制备方法 | |
CN109481400A (zh) | 一种肝靶向阿霉素/Bcl-2 siRNA共载纳米胶束及其制备方法和应用 | |
CN104069501B (zh) | 一种基于pamam的靶向给药载体及其制备方法 | |
CN114306205B (zh) | 具有肺靶向的肝素-多肽双重接枝环糊精骨架组合物及其制备方法与应用 | |
CN108570094A (zh) | Ae多肽及其在制备肿瘤靶向诊治递药系统中的用途 | |
CN108586722B (zh) | 末端含硫辛酰基的星型聚合物、其制备方法及由其制备的聚合物纳米粒子与应用 | |
CN105997867B (zh) | 功能性药物组合物的制备方法 | |
CN108392471A (zh) | 基于末端含硫辛酰基星型聚合物的纳米药物 | |
CN113082221A (zh) | Tyr/Ang双重修饰的青蒿琥酯纳米靶向制剂的制备方法和在颅脑肿瘤治疗中的应用 | |
CN108503844A (zh) | 基于聚二硫醚和聚磷酸酯的还原敏感型共聚物及其制备方法与应用 | |
CN108498458A (zh) | 一种基于普鲁兰多糖的用于超声控制释放的纳米药物载体、药物载体系统及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160726 Address after: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215123 Xinghu Street No. 218 Nano Technology Park building C25 Applicant after: Borui Pharmaceutical (Suzhou) Limited by Share Ltd Address before: 215123 Suzhou City, Suzhou Province Industrial Park, No. love road, No. 199 Applicant before: Soochow University |
|
GR01 | Patent grant | ||
GR01 | Patent grant |